• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: PREVIOUS CONGRESSES

Need for early, aggressive treatment in RRMS

October 18, 2010  

New data on fingolimod in RRMS

October 18, 2010  

Treatment discontinuations common in CIS

October 15, 2010  

Switching to fingolimod: TRANSFORMS extension study results

October 15, 2010  

TEMSO phase III results for teriflunomide

October 15, 2010  

Investigating interaction of environmental, genetic factors in MS

October 14, 2010  

Benign MS: database analysis

October 14, 2010  
1
2
3
4

Browse by Topic

MS (361)
AD (83)
PD (78)
COVID-19 (58)
PREVIOUS CONGRESSES (37)
DEPRESSION (36)
BIOMARKERS IN MS (27)
MIGRAINE (26)
SCHIZOPHRENIA (25)
EPILEPSY (22)
STROKE (22)
Library (14)
ECTRIMS 2015 (13)
CLINICAL CASES IN MS (12)
AAN 2015 (11)
ECTRIMS 2014 (10)
ECTRIMS 2019 (10)
ECTRIMS 2021 (10)
DEMENTIA (10)
ECTRIMS 2013 (9)
MS SEQUENCING (9)
AAN 2013 (9)
ECTRIMS 2018 (9)
AAN 2014 (9)
PSYCHIATRY (8)
ACTRIMS-ECTRIMS 2020 (7)
AAN 2019 (7)
CHARCOT 2013 (6)
ECTRIMS 2022 (6)
ECTRIMS 2017 (6)
AAN 2021 (6)
ANXIETY (5)
AAN 2022 (5)
ECTRIMS 2016 (5)
CCSVI (5)
BIPOLAR (5)
BPD (4)
AAN 2023 (4)
NeuroSound (4)
EAN 2015 (4)
EAN 2022 (3)
EAN 2023 (3)
AAN 2017 (3)
AAN 2020 (3)
ENS 2013 (3)
PAIN (3)
NEW DRUGS (2)
APA 2014 (2)
SLEEP (2)
ECTRIMS-ACTRIMS 2023 (2)
EAN 2020 (2)
CMSC 2023 (2)
AAN 2018 (2)
SPECIAL REPORT (2)
ACTRIMS 2023 (1)
GUIDELINES (1)
ACTRIMS 2022 (1)
ECTRIMS (1)
NEWS IN BRIEF (1)
CONCUSSION (1)
LUMBAR PUNCTURE (1)
EAN (1)
EAN 2021 (1)
WEST NILE (1)
AAN 2016 (1)
ALS (1)
LGS (1)
TSC (1)
hATTR (1)
Dravet syndrome (1)
CIDP (1)
ADDICTION (1)
EAN 2019 (1)
APA 2016 (1)
INSOMNIA (1)
SEIZURE (1)
BIOMARKERS (0)
EAN 2016 (0)
ECTRIMS 2020 (0)
AAN (0)
View all Topics

Popular Posts

  • CNS effects of Wegovy (semaglutide) posted on February 28, 2023
  • CLINICAL CASES IN MS – WORSENING SYMPTOMS PRIOR TO OCRELIZUMAB INFUSION posted on September 27, 2023
  • Ofatumumab – update on long-term efficacy, safety posted on September 25, 2023
Copyright 2023 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions